QS Research · Michael Burry's Scion Capital analyst template · 2006
SkyAI, Inc. (SKYA)
As of 2026-11-22 · 11/15 boxes filled from SEC filings and market data
Report price $2.18 (close 2026-11-20)
Conclusion: PASS
Conviction low · base case none · downside -40% · upside +38%
The market is pricing SKYA as a balance-sheet event, not an operating business: at $2.18 it pays 0.46x the $241.2M of shareholders' equity and 575.07x TTM revenue of $192,780, while TTM net income is -$207.3M. That makes the equity a claim on cash and book value rather than on earnings, so the call is PASS at low conviction. The downside is -40.5% to $1.30, based on -30.0% book value at a compressed P/B of 0.39x (today 0.46x). There is no base case: no independent multiple—peer median or own history—was available, and no comparable peer multiple sets one. The upside is +38.0% to $3.01, the analyst's own upside (no earnings change was given to price it). With the spread between those two cases, there is not enough to support a different call.
Key numbers
- Share price: $2.18
- Market cap: $110.9M
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $192,780
- Price / book: 0.46x
- Earnings-quality flags (TTM): Mark-to-market on the company's own stock (warrants) -$7.4M (4% of net income)
The 15 boxes
- ✓ 1. Long-form business notes
SkyAI, Inc., formerly Sharps Technology Inc. until 2026-05-15, moved from a pre-commercial safety-syringe developer to a medical-device distributor plus a Solana treasury vehicle: the FY2025 10-K says it adopted a SOL treasury strategy on Aug 23, 2025 and raised ~$400M in a PIPE on Aug 28, 2025. The legacy business designed and patented safety syringes and signed Nephron distribution/manufacturing agreements in 2022, but total revenue was only $204,120 in FY2025 and $192,780 TTM to Sep 2026, with negative gross profit and operating cash flow. The SOL treasury now dominates the balance sheet and earnings: SOL is marked to fair value through net income, and a related-party consultant is paid 2.5% of the $400M digital-asset base ($10M) for the first year.
- ○ 2. Competitive advantage
On GAAP figures, no durable competitive advantage is evidenced: SkyAI is an early-stage syringe seller/distributor with FY2025 revenue of $204,120, negative gross profit of $413,325, and operating income of -$269.7 million; for the TTM to 2026-09-30 revenue was $192,780, gross profit -$691,591, and operating income -$199.3 million. It competes with many medical device companies offering safety syringes, some with considerably more financial resources, and the 10-K reports net losses of $282.5 million for FY2025. The SOL-focused digital asset treasury, holding approximately 2,000,000 SOL, is a capital strategy rather than an operating moat.
- ✓ 3. 10-Q takeaways
Q3 2026 was a staking-and-treasury quarter, not an operating one: product revenue was $0 versus $68,040, net staking revenue was $2,551,013, and the $84.9 million of net income came from a $90,525,120 unrealized Solana gain (nine months to Sep 2026: net loss of $24.6 million, driven by $17,531,835 of realized crypto losses). Cash fell to $7,477,772 at September 30, 2026 from $10,382,745, with $9,145,283 used in operations and $3,112,399 spent on buybacks. After quarter-end the company sold about 2.0 million SOL for about $215 million at a roughly $163 million realized loss, leaving about $224 million of cash against a self-tender that could cost about $214.3 million if fully subscribed.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.